X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs AUROBINDO PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB AUROBINDO PHARMA DR. REDDYS LAB/
AUROBINDO PHARMA
 
P/E (TTM) x 32.0 18.8 169.8% View Chart
P/BV x 3.4 4.7 72.3% View Chart
Dividend Yield % 0.8 0.3 233.5%  

Financials

 DR. REDDYS LAB   AUROBINDO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
AUROBINDO PHARMA
Mar-17
DR. REDDYS LAB/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,788895 311.5%   
Low Rs1,902622 305.7%   
Sales per share (Unadj.) Rs860.8254.6 338.1%  
Earnings per share (Unadj.) Rs57.139.3 145.3%  
Cash flow per share (Unadj.) Rs122.046.6 261.9%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %0.90.3 258.8%  
Book value per share (Unadj.) Rs757.7160.0 473.7%  
Shares outstanding (eoy) m165.91585.88 28.3%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.73.0 91.4%   
Avg P/E ratio x41.119.3 212.8%  
P/CF ratio (eoy) x19.216.3 118.0%  
Price / Book Value ratio x3.14.7 65.3%  
Dividend payout %35.06.4 550.6%   
Avg Mkt Cap Rs m389,034444,390 87.5%   
No. of employees `00023.514.0 168.2%   
Total wages/salary Rs m32,14917,678 181.9%   
Avg. sales/employee Rs Th6,070.810,667.8 56.9%   
Avg. wages/employee Rs Th1,366.61,264.3 108.1%   
Avg. net profit/employee Rs Th402.51,645.8 24.5%   
INCOME DATA
Net Sales Rs m142,810149,157 95.7%  
Other income Rs m1,5521,159 133.9%   
Total revenues Rs m144,362150,316 96.0%   
Gross profit Rs m23,51234,343 68.5%  
Depreciation Rs m10,7724,276 251.9%   
Interest Rs m788667 118.1%   
Profit before tax Rs m13,50430,558 44.2%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3807,597 57.7%   
Profit after tax Rs m9,46823,012 41.1%  
Gross profit margin %16.523.0 71.5%  
Effective tax rate %32.424.9 130.5%   
Net profit margin %6.615.4 43.0%  
BALANCE SHEET DATA
Current assets Rs m104,98492,062 114.0%   
Current liabilities Rs m68,93866,223 104.1%   
Net working cap to sales %25.217.3 145.7%  
Current ratio x1.51.4 109.5%  
Inventory Days Days74106 70.2%  
Debtors Days Days10468 153.1%  
Net fixed assets Rs m104,38562,919 165.9%   
Share capital Rs m830586 141.7%   
"Free" reserves Rs m124,88693,133 134.1%   
Net worth Rs m125,71693,719 134.1%   
Long term debt Rs m25,0891,814 1,383.1%   
Total assets Rs m225,443162,494 138.7%  
Interest coverage x18.146.8 38.8%   
Debt to equity ratio x0.20 1,031.1%  
Sales to assets ratio x0.60.9 69.0%   
Return on assets %4.514.6 31.2%  
Return on equity %7.524.6 30.7%  
Return on capital %9.732.7 29.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62375,838 95.8%   
Fx outflow Rs m18,91630,224 62.6%   
Net fx Rs m53,70745,613 117.7%   
CASH FLOW
From Operations Rs m18,03032,786 55.0%  
From Investments Rs m-14,883-17,870 83.3%  
From Financial Activity Rs m-4,440-19,153 23.2%  
Net Cashflow Rs m-1,236-4,239 29.2%  

Share Holding

Indian Promoters % 25.5 54.1 47.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 8.0 67.9%  
FIIs % 35.3 27.7 127.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.2 150.0%  
Shareholders   75,885 69,601 109.0%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ALEMBIC LTD  SHASUN PHARMA  SANOFI INDIA  FDC LTD.  SUN PHARMA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Lower; FMCG & IT Stocks Witness Losses(Closing)

After opening the day on a positive note today, Indian share markets witnessed losses thereafter and ended their trading session marginally lower.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 26, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - DISHMAN PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS